Citations for: Bartsch, V., Gynaecological uses of dienogest alone and in combination with oestrogens. Journal of Medical Drug Reviews 2015, 5, 1-31.

Entry Type
Name
Value
Parent Entry
Pharmacology Data Field
Androgen Receptor Activity
Antagonist (40% of CPA, the most potent anti-androgenic progestin)
Dienogest (API)
Pharmacology Data Field
Estrogen Receptor Activity
Weak or no agonist and antagonist activity
Dienogest (API)
Pharmacology Data Field
Bioavailability
90-96.2%
Dienogest (API)
Pharmacology Data Field
Serum Protein Binding
90% bound to serum albumin, 10% free. No binding to SHBG or CBG.
Dienogest (API)
Pharmacology Data Field
Mineralocorticoid Receptor Activity
Antagonist (antimineralocorticoid or aldosterone antagonist). Agonist reports vary: "weak" (Africander) to "strong" (Bartsch).
Drospirenone (API)
Pharmacology Data Field
Estrogen Receptor Activity
Antagonist
Levonorgestrel (API)
Pharmacology Data Field
Glucocorticoid Receptor Activity
Conflicting reports: not active (Ruan, Lello), weakly effective (Nath), active (Bartsch), binds to GR (Jordan), low affinity (Africander)
Levonorgestrel (API)
Pharmacology Data Field
Glucocorticoid Receptor Activity
Reports vary: "weak" (Kuhl), "active" (Bartsch), "not active" (Ruan, Lello)
Etonogestrel (API)
Pharmacology Data Field
Androgen Receptor Activity
Antagonist
Progesterone (API)
Pharmacology Data Field
Mineralocorticoid Receptor Activity
"weak partial agonist" (Africander), active agonist (Bartsch). Antagonist.
Progesterone (API)